Serina Therapeutics, Inc.
AMEX: SER0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- New York Stock Exchange American
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Steven A. Ledger
- Employees
- 12
- Headquarters
- Huntsville, United States
- IPO year
- 2000
- Market cap
- $22.7M
- Website
- https://serinatherapeutics.com
Loading SER…
Loading profile data…Frequently asked questions about SER
What does Serina Therapeutics, Inc. (SER) do?
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's...
Where does SER trade?
Serina Therapeutics, Inc. (SER) trades on the New York Stock Exchange American.
What sector is SER in?
Serina Therapeutics, Inc. (SER) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Serina Therapeutics, Inc.?
Steven A. Ledger is the chief executive officer of Serina Therapeutics, Inc. (SER).
Where is Serina Therapeutics, Inc. headquartered?
Serina Therapeutics, Inc. is headquartered in United States.
Does SER pay a dividend?
Serina Therapeutics, Inc. (SER) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SER go public?
Serina Therapeutics, Inc. (SER) completed its initial public offering in 2000.